Display options
Cite
Soto L, Ferrier A, Aravena O, et al. Systemic Sclerosis Patients Present Alterations in the Expression of Molecules Involved in B-Cell Regulation. Front Immunol. 2015;6:496doi: 10.3389/fimmu.2015.00496.
Soto, L., Ferrier, A., Aravena, O., Fonseca, E., Berendsen, J., Biere, A., Bueno, D., Ramos, V., Aguillón, J. C., & Catalán, D. (2015). Systemic Sclerosis Patients Present Alterations in the Expression of Molecules Involved in B-Cell Regulation. Frontiers in immunology, 6496. https://doi.org/10.3389/fimmu.2015.00496
Soto, Lilian, et al. "Systemic Sclerosis Patients Present Alterations in the Expression of Molecules Involved in B-Cell Regulation." Frontiers in immunology vol. 6 (2015): 496. doi: https://doi.org/10.3389/fimmu.2015.00496
Soto L, Ferrier A, Aravena O, Fonseca E, Berendsen J, Biere A, Bueno D, Ramos V, Aguillón JC, Catalán D. Systemic Sclerosis Patients Present Alterations in the Expression of Molecules Involved in B-Cell Regulation. Front Immunol. 2015 Sep 29;6:496. doi: 10.3389/fimmu.2015.00496. eCollection 2015. PMID: 26483788; PMCID: PMC4586944.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2015 Sep 29;6:496. doi: 10.3389/fimmu.2015.00496. eCollection 2015.

Systemic Sclerosis Patients Present Alterations in the Expression of Molecules Involved in B-Cell Regulation.

Frontiers in immunology

Lilian Soto, Ashley Ferrier, Octavio Aravena, Elianet Fonseca, Jorge Berendsen, Andrea Biere, Daniel Bueno, Verónica Ramos, Juan Carlos Aguillón, Diego Catalán

Affiliations

  1. Programa Disciplinario de Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile , Santiago , Chile ; Hospital Clínico, Universidad de Chile , Santiago , Chile.
  2. Programa Disciplinario de Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile , Santiago , Chile ; Millennium Institute on Immunology and Immunotherapy , Santiago , Chile.
  3. Hospital Clínico, Universidad de Chile , Santiago , Chile.

PMID: 26483788 PMCID: PMC4586944 DOI: 10.3389/fimmu.2015.00496

Abstract

The activation threshold of B cells is tightly regulated by an array of inhibitory and activator receptors in such a way that disturbances in their expression can lead to the appearance of autoimmunity. The aim of this study was to evaluate the expression of activating and inhibitory molecules involved in the modulation of B cell functions in transitional, naive, and memory B-cell subpopulations from systemic sclerosis patients. To achieve this, blood samples were drawn from 31 systemic sclerosis patients and 53 healthy individuals. Surface expression of CD86, MHC II, CD19, CD21, CD40, CD22, Siglec 10, CD35, and FcγRIIB was determined by flow cytometry. IL-10 production was evaluated by intracellular flow cytometry from isolated B cells. Soluble IL-6 and IL-10 levels were measured by ELISA from supernatants of stimulated B cells. Systemic sclerosis patients exhibit an increased frequency of transitional and naive B cells related to memory B cells compared with healthy controls. Transitional and naive B cells from patients express higher levels of CD86 and FcγRIIB than healthy donors. Also, B cells from patients show high expression of CD19 and CD40, whereas memory cells from systemic sclerosis patients show reduced expression of CD35. CD19 and CD35 expression levels associate with different autoantibody profiles. IL-10(+) B cells and secreted levels of IL-10 were markedly reduced in patients. In conclusion, systemic sclerosis patients show alterations in the expression of molecules involved in B-cell regulation. These abnormalities may be determinant in the B-cell hyperactivation observed in systemic sclerosis.

Keywords: FcγRIIb; IL-10; Siglec; regulatory B cells; systemic sclerosis

References

  1. Curr Top Microbiol Immunol. 2006;305:213-40 - PubMed
  2. Arthritis Res Ther. 2010;12(2):R68 - PubMed
  3. Immunity. 2010 Jan 29;32(1):129-40 - PubMed
  4. Blood. 2012 Jul 19;120(3):581-91 - PubMed
  5. Autoimmun Rev. 2012 Jul;11(9):670-7 - PubMed
  6. Sci Transl Med. 2013 Feb 20;5(173):173ra23 - PubMed
  7. Blood. 2005 Jun 1;105(11):4390-8 - PubMed
  8. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12319-24 - PubMed
  9. J Immunol. 2009 Jan 15;182(2):890-901 - PubMed
  10. J Immunol. 2000 Dec 1;165(11):6635-43 - PubMed
  11. Am J Pathol. 2004 Aug;165(2):641-50 - PubMed
  12. Arthritis Rheum. 1980 May;23(5):581-90 - PubMed
  13. Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii80-4 - PubMed
  14. Nat Rev Rheumatol. 2014 Jul;10(7):422-8 - PubMed
  15. J Autoimmun. 2011 May;36(3-4):228-38 - PubMed
  16. Clin Immunol. 2010 Dec;137(3):322-9 - PubMed
  17. Int Immunol. 2008 Feb;20(2):185-92 - PubMed
  18. Annu Rev Immunol. 2012;30:221-41 - PubMed
  19. J Clin Invest. 2007 Mar;117(3):557-67 - PubMed
  20. J Exp Med. 2006 Sep 4;203(9):2157-64 - PubMed
  21. J Clin Invest. 2002 Jun;109(11):1453-62 - PubMed
  22. J Exp Med. 2008 Apr 14;205(4):883-95 - PubMed
  23. Immunol Res. 2000;22(2-3):281-98 - PubMed
  24. Tissue Antigens. 2007 Mar;69(3):242-9 - PubMed
  25. Arthritis Rheum. 2004 Jun;50(6):1918-27 - PubMed
  26. N Engl J Med. 2009 May 7;360(19):1989-2003 - PubMed
  27. Arthritis Rheum. 2006 Jan;54(1):192-201 - PubMed
  28. Joint Bone Spine. 2013 Jan;80(1):18-22 - PubMed
  29. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S42-6 - PubMed
  30. J Immunol. 2002 Mar 15;168(6):2782-8 - PubMed
  31. J Immunol. 2007 Mar 1;178(5):3272-80 - PubMed
  32. Mol Immunol. 2009 Sep;46(14):2767-73 - PubMed
  33. J Rheumatol. 2011 Apr;38(4):642-51 - PubMed
  34. J Immunol. 1997 Oct 15;159(8):3782-91 - PubMed
  35. Nat Rev Immunol. 2010 May;10(5):328-43 - PubMed
  36. Immunol Rev. 2009 May;229(1):152-72 - PubMed
  37. Rheumatology (Oxford). 2012 Sep;51(9):1540-9 - PubMed
  38. Int Immunol. 2013 Jan;25(1):25-33 - PubMed
  39. J Immunol. 2011 Feb 15;186(4):2080-6 - PubMed
  40. Nat Rev Immunol. 2008 Jan;8(1):34-47 - PubMed

Publication Types